|
KMID : 1100220060050010005
|
|
Dementia and Neurocognitive Disorders
2006 Volume.5 No. 1 p.5 ~ p.11
|
|
|
Biomakers for Alzheimer’s Disease
|
|
Sohn Ji-Hoon
Hong Hyun-Joo
Jin Seok-Min
Mook In-Hee
|
|
|
Abstract
|
|
|
|
Alzheimer’s disease (AD) is a neurodegenerative disorder. The number of patient is rapidly increasing with the aging society. Thus, there is a pressing need for early diagnosis and prevention of AD. AD is characterized by two major neurological features; abundant deposition of senile plaques, which is regard as a pivotal participant in the neuropathology in AD, and neurofibrillary tangles in the brain. The heterogeneity and complexity of the disease, however, seem not to allow a sole maker to discriminate AD patients from normal with a sufficient specificity and sensitivity. Although their accuracy is still controversial, several biochemical markers for AD are now available, including reduced Aβprotein, increased phosphorylated tau protein in cerebrospinal fluid, and elevated level of glial fibrillary acidic protein (GFAP) autoantibody in the serum. Not only that, some remarkable progress also has been made in brain imaging fields with an aid of swiftly developing technologies. Here, we overlook both biochemical markers, rather focus on Aβand tau related ones, and imaging techniques for the diagnosis of AD. Some areas where more work is required are discussed as well.
|
|
|
KEYWORD
|
|
|
Alzheimer’s disease, Biomarker, CSF, Serum, Plasma, Brain Imaging, Aβ, Tau
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|